|Day Low/High||3.77 / 4.04|
|52 Wk Low/High||1.46 / 8.05|
New Preclinical Data to be Presented on First-of-Kind Product Candidates Derived from Master Engineered Pluripotent Cell Lines
Some small names are interesting, but more-aggressive position trades are not developing right now.
Insiders have an edge in this complex sector, so it's worth checking them out.
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
Traders are also looking for smaller-caps that can move big around the holiday.
Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTRN, FSFG, LWAY Downgrades: BAM, BT, DHT, RFIL, SNP Initiations: FATE Read on to get TheStreet Quant Ratings' detailed report: